Novel Therapies in Oncology: An Individualized Approach

Author(s): Stephanie Gregory, MS, FNP-C, BMTCN, Margaret Kelley, MSN, APN, FNP-BC, OCN, Tanya Lalani, DNP, NP, AOCNP

Contact Hours 1.00

CERP A 1.00

Pharmacology Hours 0.75

Expires May 31, 2026

Topics: Hematology/Oncology, Pharmacology

Role: APRN, Staff

Member: Free
NonMember: $10.00

Added to Collection

Activity Summary

Required reading for all learners: Implicit Bias impacts patient outcomes

This article reviews novel therapies in oncology which have made a profound difference in the treatment of cancer. The new approaches described include immune checkpoint inhibitors, antibody-drug conjugates, protein kinase inhibitors, bispecific antibodies and tumor-treating fields. The article explains each agent’s mechanisms of action and the management of adverse events that require critical care interventions.


  • Explain novel therapies in oncology and their mechanisms of action
  • Describe potential adverse events related to novel therapies in oncology that may require critical care team management
  • Identify patient care considerations when caring for a patient with a tumor treating fields device

Continuing Education Disclosure Statement

Successful Completion

Learners must attend/view/read the entire activity, read Implicit Bias impacts patient outcomes, and complete the associated evaluation to be awarded the contact hours or CERP. No partial credit will be awarded.


The American Association of Critical-Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider number CEP 1036, for 1.00 contact hours.

Accreditation refers to recognition of continuing education only and does not imply AACN, ANCC, or CBRN approval or endorsement of any commercial products discussed or displayed in conjunction with this educational activity.


Any relevant relationship between an ineligible company and an individual with the ability to influence clinical content will be identified by the Nurse Planner within the activity. Any relevant relationship between an ineligible company and an individual with the ability to influence clinical content has been mitigated.

AACN programming meets the standards for most states that require mandatory continuing education contact hours for license and/or certification renewal. AACN recommends consulting with your state board of nursing or credentialing organization before submitting CE to fulfill continuing education requirements.

Refund Policy

Continuing Education Activities are nonrefundable.